FMP
Dec 15, 2025(Last modified: Dec 16, 2025)
MongoDB Inc. (NASDAQ:MDB) is a leading provider of database solutions, known for its innovative NoSQL database platform. The company offers a flexible and scalable database solution that caters to a wide range of applications, making it a popular choice among developers and businesses. MongoDB competes with other database providers like Oracle and Microsoft, which offer traditional relational database solutions.
On December 15, 2025, Raymond James adjusted its rating for MongoDB to "Market Perform," a shift from its previous "Strong Buy" recommendation. At the time, the stock was priced at $415.97, as reported by TheFly. This change in rating reflects a more cautious outlook on the stock's future performance, despite its recent price movements.
MongoDB has seen a 2.29% increase in its stock price over the past week, making it attractive to momentum investors. Momentum investing focuses on stocks that are trending, with the expectation that the trend will continue. MongoDB's Momentum Style Score of B, as noted by Zacks Investment Research, indicates a strong potential for continued price movement.
Despite the recent positive momentum, MongoDB's stock price has decreased by $3.03, or approximately -0.72%, to $415.97. The stock has traded between $412 and $420.86 today, showing some volatility. Over the past year, the stock has reached a high of $432.55 and a low of $140.78, highlighting its potential for significant price swings.
MongoDB's market capitalization stands at approximately $33.86 billion, reflecting its substantial presence in the database industry. With a trading volume of 1,344,492 shares for the day, the stock remains actively traded on the NASDAQ exchange. This level of activity indicates continued interest from investors, despite the recent rating adjustment by Raymond James.
Akamai Technologies Inc. (NASDAQ: AKAM) is a key player in the computer and technology sector, known for its cloud servi...
Immunome, Inc. (NASDAQ:IMNM) is a biotechnology company focused on developing innovative cancer therapies. On December 1...